Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07262450

Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms

The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.

The main questions it aims to answer are:

* Efficacy, * Safety, * Usage, * Satisfaction, in real-life usage among infants, children, adults and pregnant or breastfeeding women suffering from acute and chronic sinonasal pathologies. The 4 medical devices under investigation will be used in accordance with their intended use, target populations and medical indications.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject's age and medical condition in compliance with the intended use and population
  • Subjects who, from the investigator's judgement, should benefit from nasal wash in accordance with routine medical practice
  • Subjects with at least two nasal symptoms of intensity ≥ 3 (6 modalities intensity SNOT-22 rating-scale) among the following:
  • Nasal blockage/nasal congestion/ stuffy nose;
  • Runny nose;
  • Need to blow/clear the nose;
  • Sneezing;
  • Thick nasal discharge/secretions;
  • Decreased sense of smell /taste (replaced by "noisy breathing/mouth breathing" for infants)
  • Subjects with impaired nasal breathing (score ≥ 3, 6-modalities intensity rating-scale), induced by the presence of nasal symptoms
  • For acute indications (only): subjects with symptoms started not later than 72 hours prior to enrolment (Day 0).
  • For allergic rhinitis indication: perennial allergic rhinitis with and without seasonal allergic rhinitis
  • For post-surgery indication: septoplasty and rhinoseptoplasty.
  • Subject/parent willing to perform nasal wash following advices received from HCPs.
  • Subjects (or parents for babies and children) agreeing to follow the study requirements during the whole study period (up to 3 months).
  • Subject (or parent for baby and children) able to understand verbal and written local language and in capacity to fill-in questionnaire by himself.
  • Subject having daily access to internet to answer online questionnaire.
  • Subject or Parent/legal guardian of the subject has given freely and expressly her/his informed consent.
  • Subject affiliated to the health social security system or beneficiary of an equivalent system

Non-inclusion criteria:

  • Subject with contraindications according to each IFU.
  • Hypersensitivity or known allergy to any component of the investigational products.
  • Subject taking part in another clinical study or being in the exclusion period of another clinical study.
  • Subject already using nasal wash to manage his nasal symptoms.
  • Subject already included once in the study.
  • Subject with a member of his household already included in the study if still in the follow-up phase.
  • Subject deprived of liberty by administrative or judicial decision or under legal guardianship.

Treatment and study plan

Respimer® Hygiene-Prevention -Baby, kids, adults

Device

1-3 seconds spray in each nostril,

  • 4 to 6 times a day, in treatment of nasal symptoms.
  • 1 to 2 times a day, in hygiene and prevention

Respimer® Hygiene-Prevention Kids, adults

Device

1-2 seconds spray in each nostril,

  • 4 to 6 times a day, in treatment of nasal symptoms
  • 1 to 2 times a day, in hygiene and prevention

Respimer® Decongestion Baby, kids, adults

Device

Baby (2 months+): 1-3 seconds spray in each nostril, up to 3 times a day Children (2 y+) and adults: 1-3 seconds spray in each nostril, up to 6 times a day

Phytosun arôms® Hypertonic nasal wash

Device

1 second spray in each nostril, 2-3 times a day.

Primary outcomes

  1. Real-life effectiveness to improve nasal symptoms in case of acute and chronic sinonasal pathologies.

    Time frame: From Day 0 to Day 5 (acute indications: URTI, COVID-19, bronchiolitis) From Day 0 to Day 14 (chronic indications: allergic rhinitis, chronic rhinosinusitis, post-surgery)

    Change from baseline in nasal symptom intensity following initiation of nasal wash, based on the modified SNOT-22 rhinologic score. 6-modalities intensity Likert scale: 0=No problem; 1= Very mild problem; 2=Mild or slight problem; 3= Moderate problem; 4=Severe problem; 5=Problem as bad as it can be.

Secondary outcomes

  1. Real-life effectiveness to reduce the intensity of individuals symptoms

    Time frame: From Day 0 to Day 14

    Daily change from baseline in individual symptoms intensity. 6-modalities intensity Likert scale.

  2. Real-life effectiveness to reduce the intensity of additional extra nasal symptoms

    Time frame: From Day 0 to Day 14

    Daily change from baseline in additional extra nasal symptoms intensity. 6-modalities intensity Likert scale.

  3. Real-life effectiveness to reduce the intensity of eyes symptoms

    Time frame: From Day 0 to Day 14

    Daily change from baseline in eyes symptoms intensity. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): 6-modalities scale.

  4. Real-life effectiveness to reduce the daily intensity of symptoms

    Time frame: From Day 0 to Day 14

    Proportion of patients presenting a daily change in symptoms intensity; Modified SNOT-22: 6-modalities intensity Likert scale. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): 6-modalities scale

  5. Real-life effectiveness to reduce the overall intensity of symptoms

    Time frame: From Day 0 to Day 14

    Daily change from baseline in the global modified SNOT-22 score and domains

  6. Real-life effectiveness to reduce the frequency of sneezing

    Time frame: From Day 0 to Day 14

    Daily change from baseline in sneezing frequency. 5-modalities sneezing frequency scale

  7. Real-life effectiveness to reduce the frequency of nose blowing

    Time frame: From Day 0 to Day 14

    Daily change from baseline in nose blowing frequency. 6-modalities nose blowing frequency scale

  8. Real-life effectiveness to reduce the frequency of cough

    Time frame: From Day 0 to Day 14

    Daily change from baseline in cough frequency. 6-modalities Cough Symptom Score

  9. Real-life effectiveness to relieve individual symptoms - Evolution

    Time frame: From Day 0 to Day 14

    Daily evolution of individual symptoms relief. Symptoms relief scale: 7-modalities scale

  10. Real-life effectiveness to relieve individual symptoms

    Time frame: From Day 0 to Day 14

    Proportion of patients reporting a daily symptom relief. Symptoms relief scale: 7-modalities scale

  11. Real-life effectiveness to relieve individual symptoms - 1st relief

    Time frame: From Day 0 to Day 14

    Number of days until first symptom relief. Symptoms relief scale: a 7-modalities scale

  12. Real-life effectiveness to improve nasal breathing

    Time frame: From Day 0 to Day 14

    Daily change from baseline in nasal breathing difficulty. Nasal breathing difficulty scale: 6-modalities scale

  13. Real-life effectiveness to improve nasal breathing - Onset

    Time frame: From Day 0 to Day 14

    Time to perceived improvement of nasal breathing. Nasal breathing scale: 7-modalities rating scale

  14. Real-life effectiveness to improve nasal breathing - Duration

    Time frame: From Day 0 to Day 14

    Duration of improved nasal breathing. Improved nasal breathing scale: 7-modalities questionnaire

  15. Real-life effectiveness to improve nasal breathing - Time interval

    Time frame: From Day 0 to Day 14

    Daily average time between two consecutive nasal washes. Open question whose unit of measurement is in hours

  16. Real-life effectiveness to improve nasal blowing/removal of secretions

    Time frame: From Day 0 to Day 14

    Daily change from baseline in nose blowing/removal of secretions Easiness to blow the nose/remove secretions scale: 5-modalities rating scale

  17. Real-life effectiveness to improve quality of secretions

    Time frame: From Day 0 to Day 14

    Daily change from baseline in quality of nasal secretions. Quality of nasal secretions scale: 4-modalities rating scale

  18. Real-life effectiveness to improve quality of life

    Time frame: From Day 0 to Day 14

    Daily change from baseline in subjects' quality of life. QOL items of the modified SNOT-22 questionnaire: 6-modalities intensity Likert scale

  19. Real-life effectiveness to improve quality of life - Energy

    Time frame: From Day 0 to Day 14

    Daily change from baseline in loss of energy. 4-modalities rating energy scale

  20. Real-life effectiveness to improve quality of life - Daily activities

    Time frame: From Day 0 to Day 14

    Daily change from baseline in symptoms interference with daily activities. Symptom interference scale: 5-modalities rating scale

  21. Real-life effectiveness to improve quality of life - Feeding difficulties

    Time frame: From Day 0 to Day 14

    Daily change from baseline in feeding difficulties. Babies's feeding difficulty scale: 0-10 VAS scale

  22. Real-life effectiveness to improve quality of life - Baby and young child

    Time frame: From Day 0 to Day 14

    Daily change from baseline in cries frequency, irritability, comfort and wellbeing, overall behaviour.

    Baby and young child quality of life scale: 6-modalities rating scale.

  23. Real-life effectiveness to improve quality of life of the family

    Time frame: From Day 0 to Day 14

    Daily change from baseline in family/parental quality of life. Family/parental quality of life scale: 6-modalities rating scale

  24. Real-life effectiveness to limit nasal symptoms during winter and allergy seasons

    Time frame: From Day 15 to 3 months

    Number and proportion of subjects with nasal symptoms. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale

  25. Real-life effectiveness to limit nasal symptoms during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number of nasal symptoms per subject. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale

  26. Real-life effectiveness to limit nasal symptoms during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Evolution of nasal symptoms intensity. SNOT-22 self-questionnaire: 6-modalities intensity Likert scale

  27. Real-life effectiveness to limit nasal symptoms during winter and allergy seasons - Sneezing frequency.

    Time frame: From Day 15 to 3 months

    Evolution of sneezing frequency. 5-modalities sneezing frequency scale

  28. Real-life effectiveness to limit nasal symptoms during winter and allergy seasons - Nose blowing.

    Time frame: From Day 15 to 3 months

    Evolution of nose blowing/Need to rub the nose frequency. 6-modalities nose blowing frequency scale

  29. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number and proportion of subjects with extra-nasal symptoms. Modified SNOT-22 self questionnaire: 6-modalities scale

  30. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number of extra-nasal symptoms per subject. Modified SNOT-22 self questionnaire: 6-modalities scale

  31. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Evolution of extra-nasal symptoms intensity. Modified SNOT-22 self questionnaire: 6-modalities scale

  32. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons - Eyes symptoms.

    Time frame: From Day 15 to 3 months

    Evolution of eyes symptoms intensity for allergic rhinitis sufferers. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ):7-point Likert scale

  33. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Evolution of modified SNOT-22 domains. Modified SNOT-22 self-questionnaire: 6-modalities scale

  34. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons .

    Time frame: From Day 15 to 3 months

    Evolution of modified SNOT-22 global score. Modified SNOT-22 self-questionnaire: 6-modalities scale

  35. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons - Cough, snoring, wake-up at night.

    Time frame: From Day 15 to 3 months

    Evolution of cough, snoring, wake up at night. Snoring, wake up at night (due to symptoms), cough frequency scale: 7-modalities rating scale

  36. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons - Acute respiratory infections.

    Time frame: From Day 15 to 3 months

    Number and proportion of subjects with acute respiratory infection. Multiple-choice question regarding acute respiratory infection including the start date of the symptoms.

  37. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons - Allergic rhinitis episodes.

    Time frame: From Day 15 to 3 months

    Number and proportion of subjects with acute allergic rhinitis episodes (for allergic rhinitis sufferers).

    Open question whose unit of measurement is in number of episodes.

  38. Real-life effectiveness to limit extra-nasal symptoms during winter and allergy seasons - Asthma episodes.

    Time frame: From Day 15 to 3 months

    Number and proportion of subjects with asthma episodes/exacerbations (for allergic rhinitis sufferers).

    Open question whose unit measurement is in number of episodes.

  39. Real-life effectiveness to improve nasal breathing quality during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Evolution of nasal breathing score. Nasal breathing difficulty scale: 6-modalities scale

  40. Real-life effectiveness to improve quality of life (QOL) during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Evolution in modified SNOT-22 quality of life items. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale

  41. Real-life effectiveness to improve quality of life (QOL) during winter and allergy seasons - Energy.

    Time frame: From Day 15 to 3 months

    Evolution in loss of energy. 4-modalities rating energy scale

  42. Real-life effectiveness to improve quality of life (QOL) during winter and allergy seasons - Well-being & global health status

    Time frame: From Day 15 to 3 months

    Evolution of well-being and global health status. 0-10 VAS scale

  43. Real-life effectiveness to improve quality of life (QOL) during winter and allergy seasons - Daily activities.

    Time frame: From Day 15 to 3 months

    Evolution of symptom interference with daily activities. 5-modalities rating scale

  44. Real-life effectiveness to improve quality of life (QOL) during winter and allergy seasons - Practical problems.

    Time frame: From Day 15 to 3 months

    Evolution in practical problems (inconvenience of having to carry tissues/hankerchiefs, need to rub nose/eye, need to blow your nose repeatedly), for allergic rhinitis sufferers.

    6 modalities Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scale.

  45. Real-life effectiveness to limit the number of illness and missed days.

    Time frame: From Day 15 to 3 months

    Number of days with sickness / nasal symptoms. Open question whose unit of measurement is in number of days

  46. Real-life effectiveness to limit the number of illness and missed days.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with sickness days . Open question whose unit of measurement is in number of days

  47. Real-life effectiveness to limit the number of illness and missed days.

    Time frame: From Day 15 to 3 months

    Number of missed days (work, school, daycare). Open question whose unit of measurement is in number of days

  48. Real-life effectiveness to limit the number of illness and missed days.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with missed days (work, school, daycare). Open question whose unit of measurement is in number of days

  49. Real-life effectiveness to limit the impact on daily life for the family.

    Time frame: From Day 15 to 3 months

    Number of days of parental absence (work activities) due to baby/child's disease.

    Open question whose unit of measurement is in number of days

  50. Real-life effectiveness to limit the impact on daily life for the family .

    Time frame: From Day 15 to 3 months

    Number and percentage of parents with missed days (work, activities). Open question whose unit of measurement is in number of days

  51. Real-life effectiveness to limit the impact on daily life for the family.

    Time frame: From Day 15 to 3 months

    Number of days with impaired family/parental quality of life. Family/parental quality of life scale : 6-modalities rating scale

  52. Real-life effectiveness to limit the impact on daily life for the family .

    Time frame: From Day 15 to 3 months

    Number and percentage of parents/family with impaired quality of life. Family/parental quality of life scale: 6 modalities rating scale

  53. Real-life effectiveness to reduce the intake of concomitant medications during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with intake of medications. Questions about name of the treatment, route of administration and number of days of use for each treatement

  54. Real-life effectiveness to reduce the intake of concomitant medications during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number of days with intake of medications. Question about name of the treatment, route of administration and number of days of use for each treatement

  55. Real-life effectiveness to reduce the intake of concomitant medications during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects in control group with re-introduction of nasal wash.

    Question about the name and format of the nasal wash product and number of days of use.

  56. Real-life effectiveness to reduce the intake of concomitant medications during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Evolution of allergic rhinitis treatment for allergic rhinitis sufferers. 3-modalities scale

  57. Real-life effectiveness to reduce the evolution towards more severe form or complications.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with severe symptoms intensity. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale

  58. Real-life effectiveness to reduce the evolution towards more severe form or complications - Extra-nasal symptoms.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with severe extra-nasal symptoms intensity. Modified SNOT-22 self-questionnaire: 6-modalities intensity Likert scale

  59. Real-life effectiveness to reduce the evolution towards more severe form or complications - Eyes symptoms.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with severe eyes symptom intensity. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scale: 7-point Likert scale

  60. Real-life effectiveness to reduce the evolution towards more severe form or complications - Complications.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with occurence of complications. Multiple-choice question.

  61. Real-life effectiveness to reduce the evolution towards more severe form or complications - Asthma.

    Time frame: From Day 15 to 3 months

    Evolution of asthma symptoms frequency for asthma sufferers. 7-modalities frequency scale

  62. Real-life effectiveness to reduce the evolution towards more severe form or complications - Asthma episodes.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects with asthma episodes/exacerbation for asthma sufferers.

    Open question

  63. Real-life effectiveness to reduce the evolution towards more severe form or complications - Asthma intensity.

    Time frame: From Day 15 to 3 months

    Evolution of asthma symptoms intensity for asthma sufferers. 7-modalities scale

  64. Real-life effectiveness to reduce the need for unplanned HCP care during winter and allergy seasons.

    Time frame: From Day 15 to 3 months

    Number and percentage of subjects consulting a HCP. Collection of unplanned HCP consultations because of nasal/respiratory symptoms

  65. Real-life effectiveness to reduce the need for unplanned HCP care during winter and allergy seasons - Hospitalizations.

    Time frame: From Day 15 to 3 months

    Number and percentage of hospitalized subjects. Collection of hospitalizations due to nasal/respiratory symptoms

  66. Real-life assessment of onset and duration of action and perceived effectiveness of the sprays - Onset.

    Time frame: From Day 15 to Month 3

    Time to perceived improvement of nasal breathing. 7 modalities rating scale.

  67. Real-life assessment of onset and duration of action and perceived effectiveness of the sprays - Duration.

    Time frame: From Day 15 to Month 3

    Duration of improved nasal breathing. 7-modalities questionnaire

  68. Real-life assessment of onset and duration of action and perceived effectiveness of the sprays.

    Time frame: From Day 15 to Month 3

    Daily average time between two consecutive nasal washes. Open question whose unit of measurement is in hours

  69. Real-life assessment of onset and duration of action and perceived effectiveness of the sprays - Allergic rhinitis.

    Time frame: From Day 15 to Month 3

    Number and percentage of subjects with improved effectiveness of their usual allergic rhinitis treatment.

    7-modalities questionnaire

  70. Real-life nasal sprays usage (posology, moment of use, usage versus medication) - Posology.

    Time frame: From Day 0 to Month 3

    Number of nasal wash per day and Number of days of use per week . 8-modalities posology questionnaire

  71. Real-life nasal sprays usage (posology, moment of use, usage versus medication) - Moment of use.

    Time frame: From Day 0 to Month 3

    Moments of use of the nasal spray during the day. 7-modalities multiple choice question

  72. Real-life nasal sprays usage (posology, moment of use, usage versus medication) - Co-usage with medications.

    Time frame: From Day 0 to Month 3

    Moments of use versus medications. Co-usage questionnaire.

  73. Real-life nasal sprays usage (posology, moment of use, usage versus medication) - Occasion of use.

    Time frame: From Day 15 to Month 3

    Occasion of use during the prevention phase. Multiple-choice question

  74. Real-life nasal sprays usage (posology, moment of use, usage versus medication) - Baby nasal aspirator.

    Time frame: From Day 0 to Month 3

    Complementary usage of a baby nasal aspirator. 7-modalities frequency scale

  75. Real-life nasal sprays usage (posology, moment of use, usage versus medication) - Child autonomy.

    Time frame: From Day 0 to Month 3

    Child's autonomy in using the nasal spray. Multiple-choice question

  76. Real-life assessment of satisfaction and willingness to reuse and recommandation of the nasal sprays - Satisfaction.

    Time frame: From Day 0 to Month 3

    Number and percentage of subjects satisfied with the use of the nasal spray. 5-modalities satisfaction scale.

  77. Real-life assessment of satisfaction and willingness to reuse and recommandation of the nasal sprays - Perceived sensation.

    Time frame: From Day 0 to Month 3

    Perceived sensation after application. 5-modalities sensory scale.

  78. Real-life assessment of satisfaction and willingness to reuse and recommandation of the nasal sprays - Perceived effectiveness.

    Time frame: From Day 0 to Month 3

    Global perceived effectiveness of the nasal spray. 6-modalities rating scale

  79. Real-life assessment of satisfaction and willingness to reuse and recommandation of the nasal sprays - Practicality.

    Time frame: From Day 0 to Month 3

    Practicality of the product, easiness to use. 6-modalities technical performance agreement scale.

  80. Real-life assessment of satisfaction and willingness to reuse and recommendation of the nasal sprays - Reuse and recommend.

    Time frame: From Day 0 to Month 3

    Number and percentage of subjects with willingness to reuse, willingness to recommend the nasal spray.

    4-modalities scale

  81. Real-life assessment of satisfaction and willingness to reuse and recommandation of the nasal sprays - Educational content.

    Time frame: From Day 0 to Month 3

    Usefulness of the educational content (tutorial and tips). Multiple choice satisfaction questionnaire.

  82. Assessment of the safety and tolerance of the nasal sprays - Tolerance.

    Time frame: From Day 0 to Month 3

    Evolution of tolerance to the nasal spray. 4-modalities scale.

  83. Assessment of the safety and tolerance of the nasal sprays - Safety.

    Time frame: From Day 0 to Month 3

    Number and percentage of incidents reported during the clinical investigation. Number and percentage of subjects reporting incidents during the clinical investigation.

    Collection of incidents and adverse events (nature, dates of occurrence and evolution).

Study contacts

Contact information is provided by the study sponsor or research team.

Gaëlle NAELTEN, PharmD / PhD

CONTACT

[email protected]

+330633901291

Sponsors and collaborators

Lead sponsor

Laboratoire de la Mer

Industry

Collaborators

  • EVAMED

Registry information

Official study title

Real-word Study to Assess Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms

Acronym: SeaBridge

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 3, 2025
Registry last updated
Dec 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.